We are live on ! Find out more

Outset Medical

OM

Market cap $59.2M

3.15 USD

-0.06

1.87%

At close Updated Sep 14, 4:00 PM EDT

1 day

-1.87%

5 days

-11.52%

1 month

-30.16%

3 months

-26.91%

6 months

-5.97%

Year to date

-14.86%

1 year

-77.04%

5 years

-99.58%

10 years

-99.65%

About: Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.

Employees: 310

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 72.7%

Negative 0%

Zacks Investment Research

Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock

Outset Medical (OM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock

Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript

Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript

Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript

Outset Medical Q2 Earnings Call Highlights

Outset Medical NASDAQ: OM reported second-quarter 2026 revenue of $31.6 million, up 1% from a year earlier and 14% sequentially, as the dialysis technology company cited commercial progress, improving margins and a new $40 million refresh agreement with HCA Healthcare.

Outset Medical Q2 Earnings Call Highlights

Zacks Investment Research

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.84 per share a year ago.

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

Outset Medical Reports Second Quarter 2026 Results

SAN JOSE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the second quarter ended June 30, 2026.

Outset Medical Reports Second Quarter 2026 Results

Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

SAN JOSE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2026 after the close of trading on Thursday, August 6, 2026.

Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Outset Medical, Inc. (NASDAQ: OM) Investor Alert: Schubert Jonckheer Investigating Possible False Statements, Over $50 Million in Insider Sales

SAN FRANCISCO, July 6, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Outset Medical, Inc. (NASDAQ: OM) investors that the firm is investigating potential legal claims arising from alleged false statements about FDA clearance requirements for one of the company's key products and demand for its dialysis machines. Current shareholders are encouraged to contact the firm here: https://www.classactionlawyers.com/outset.

Outset Medical, Inc. (NASDAQ: OM) Investor Alert: Schubert Jonckheer Investigating Possible False Statements, Over $50 Million in Insider Sales

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN JOSE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's Inducement Plan, as a material inducement to employment with the Company, for one recently hired executive employee and two recently hired non-executive employees, each of whom was not previously an employee or director of the Company.

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

Outset Medical (OM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

See News Rankings

Price charts implemented using Lightweight Charts™